(0.01%) 5 479.25 points
(-0.01%) 38 816 points
(0.04%) 19 930 points
(0.30%) $80.57
(0.61%) $2.81
(0.13%) $2 332.00
(-0.29%) $29.31
(-0.05%) $970.40
(0.02%) $0.932
(-0.13%) $10.64
(0.07%) $0.788
(-1.87%) $86.80
2 days till quarter result
(bmo 2024-06-20)
Expected move: +/- 11.29%
Live Chart Being Loaded With Signals
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox...
Stats | |
---|---|
Šios dienos apimtis | 3 001 |
Vidutinė apimtis | 302 023 |
Rinkos kapitalizacija | 80.67M |
EPS | $-0.250 ( Q1 | 2024-05-01 ) |
Kita pelno data | ( $-0.220 ) 2024-06-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.960 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00500 (0.56%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-20 | Kozin Marc D | Buy | 100 000 | Stock Option (Right to Buy) |
2024-03-20 | Kozin Marc D | Buy | 0 | |
2024-02-14 | Andriole Michael T. | Sell | 1 744 | Common Stock |
2024-02-14 | Laspaluto Michelle | Sell | 1 940 | Common Stock |
2024-02-14 | Jakeman David | Sell | 2 660 | Common Stock |
INSIDER POWER |
---|
89.27 |
Last 99 transactions |
Buy: 5 160 750 | Sell: 1 392 397 |
Tūris Koreliacija
Chimerix Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
OZEM | 1 |
HLP | 0.943 |
MAMA | 0.941 |
NBBK | 0.934 |
MSAQX | 0.928 |
EVCGX | 0.926 |
FEBO | 0.925 |
MICFX | 0.919 |
MCHFX | 0.918 |
AOGO | 0.907 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
QREARX | -0.941 |
NWGL | -0.934 |
GBLMX | -0.93 |
BAER | -0.908 |
HTOOW | -0.9 |
RENB | -0.889 |
RDZN | -0.88 |
IIMFX | -0.877 |
FUFUW | -0.872 |
GGLS | -0.871 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Chimerix Inc Koreliacija - Valiuta/Žaliavos
Chimerix Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $324 000 |
Bruto pelnas: | $323 000 (99.69 %) |
EPS: | $-0.930 |
FY | 2023 |
Pajamos: | $324 000 |
Bruto pelnas: | $323 000 (99.69 %) |
EPS: | $-0.930 |
FY | 2022 |
Pajamos: | $33.82M |
Bruto pelnas: | $33.38M (98.68 %) |
EPS: | $1.970 |
FY | 2021 |
Pajamos: | $1.98M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-2.01 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Chimerix Inc
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.